Residual risk of transfusion-transmitted HCV and HIV infections by antibody-screened blood in Italy

Transfusion

Volumn 42, Issue 8, 2002, Pages 989-993

  Velati, Claudio ^a,b,c   Romanò, Luisa ^a,b,c   Baruffi, Lorella ^a,b,c   Pappalettera, Marco ^a,b,c   Carreri, Vittorio ^a,b,c   Zanetti, Alessandro R ^a,b,c  

^a Hospital of Sondrio   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c Regione Lombardia   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS ANTIBODY;

ARTICLE; BLOOD; BLOOD TRANSFUSION; DISEASE TRANSMISSION; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; ITALY; RISK ASSESSMENT;

ANTIBODIES, VIRAL; BLOOD TRANSFUSION; HEPATITIS C; HIV INFECTIONS; HUMANS; INCIDENCE; ITALY; RISK ASSESSMENT;

EID: 0036692175     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1537-2995.2002.00173.x     Document Type: Article

References (26)

1. 1 Aubuchon JP, Birkmeyer JD, Busch MP. Safety of the blood supply in the United States: opportunities and controversies. Annals Int Med 1997 ; 127: 904 ‐ 9.
2. 2 Mele A, Stroffolini T, Catapano R, et al. Incidence of transfusion associated B and non‐A, non‐B hepatitis in Italy. BMJ 1995 ; 311: 846 ‐ 7 ; erratum in BMJ 1995;311:990.
3. 3 Mele A, Tosti ME, Marzolini A, et al. Prevention of hepatitis C in Italy: lessons from surveillance of type‐specific acute viral hepatitis. SEIEVA Collaborating Group. J Viral Hepatitis 2000 ; 7: 30 ‐ 5.
4. 4 Istituto Superiore di Sanitá, AIDS Unit. AIDS cases in Italy update to December 2001. Not Sup Sanità 2002; 15(Suppl. 1).
5. 5 Kleinman SH, Busch MP, Korelitz JJ, Schreiber GB, For The Retrovirus Epidemiology Donor Study. The incidence/window period model and its use to assess the risk of transfusion‐transmitted human immunodeficiency virus and hepatitis C virus infection. Transfusion Med Rev 1997 ; 11: 155 ‐ 72.
6. 6 Regan FAM, Hewitt P, Barbara JAJ, Contreras M. Prospective investigation of transfusion transmitted infection in recipients of over 20000 units of blood. TTI study group. Brit Med J 2000 ; 320: 403 ‐ 6.
7. 7 Lackritz EM, Satten GA, Aberle‐Grasse J, et al. Estimated risk of transmission of the human immunodeficiency virus by screened blood in the United States. N Engl J Med 1995 ; 333: 1721 ‐ 5.
8. 8 Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion‐transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med 1996 ; 334: 1685 ‐ 90.
9. 9 Korelitz JJ, Busch MP, Kleinman SH, et al. A method for estimating hepatitis B virus incidence rates in volunteer blood donors. National Heart, Lung, and Blood Institute Retrovirus Epidemiology Donor Study. Transfusion 1997 ; 37: 634 ‐ 40.
10. 10 Zanetti AR. Update on hepatitis B vaccination in Italy 10 years after its implementation. Vaccine 2001 ; 19: 2380 ‐ 3.
11. 11 Bellentani S, Miglioli L, Masutti F, et al. Epidemiology of hepatitis C virus infection in Italy: the slowly unraveling mystery. Microb Infect 2000 ; 2: 1757 ‐ 63.
12. 12 Alix J, Downs AM, Hamers F, et al. Surveillance of HIV/AIDS in Europe: update at the end 2000. Euro Surveill 2001 ; 6: 84 ‐ 5.
13. 13 Nubling CM, Seitz R, Loewer J. Application of nucleic acid amplification techniques for blood donation screening. Infusionsther Transfusionsmed 1998 ; 25: 86 ‐ 90.
14. 14 Busch MP, Kleinman SH, Jackson B, et al. Nucleic acid amplification testing of blood donors for transfusion‐transmitted infectious disease. Report of the Interorganizational Task Force on Nucleic Acid Amplification Testing of Blood Donors. Transfusion 2000 ; 40: 143 ‐ 59.
15. 15 Roth WK, Weber M, Seifried E. Feasibility and efficacy of routine PCR screening of blood donations for hepatitis C virus, hepatitis B virus and HIV‐1 in a blood‐bank setting. Lancet 1999 ; 353: 359 ‐ 63.
16. 16 Roth WK, Buhr S, Drosten C, Seifried E. NAT and viral safety in blood transfusion. Vox Sang 2000 ; 78 (Suppl 2): 257 ‐ 9.
17. 17 Couroucé AM, Le Marrec N, Bouchardeau F, et al. Efficacy of HCV core antigen detection during the preseroconversion period. Transfusion 2000 ; 40: 1198 ‐ 202.
18. 18 Peterson J, Green G, Iida K, et al. Detection of hepatitis C core antigen in the antibody negative window phase of hepatitis C infection. Vox Sang 2000 ; 78: 80 ‐ 5.
19. 19 Busch MP, Dodd RY. NAT and blood safety: what is the paradigm? (letter). Transfusion 2000 ; 40: 1157 ‐ 60.
20. 20 Couroucé AM, Pillonel J. Transfusion‐transmitted viral infections. Retrovirus and viral hepatitis working groups of the french society of blood transfusion (letter). N Engl J Med 1996 ; 335: 1609 ‐ 10.
21. 21 Goodnough LT, Brecher ME, Kanter MH, Aubuchon JP. Transfusion medicine. First of two parts—Blood transfusion. N Engl J Med 1999 ; 340: 438 ‐ 47.
22. 22 Pillonel J, Saura C, Couroucé AM. Screening of viral markers for HIV, HBV and HCV infections in blood donors in France and residual risk of viral transmission by blood transfusion. Euro Surveill 1998 ; 3: 76 ‐ 9.
23. 23 Koerner K, Cardoso M, Dengler T, et al. Estimated risk of transmission of hepatitis C virus by blood transfusion. Vox Sang 1998 ; 74: 213 ‐ 6.
24. 24 Muller‐Breitkreutz K. Results of viral marker screening of unpaid blood donations and probability of window period donations in 1997. EPFA Working Group on Quality Assurance. Vox Sang 2000 ; 78: 149 ‐ 57.
25. 25 Alter MJ, Kruszon‐Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999 ; 341: 556 ‐ 62.
26. 26 Beutels M, Van Damme P, Aelvoet W, et al. Prevalence of hepatitis A, B and C in the Flemish population. Eur J Epidemiol 1997 ; 13: 275 ‐ 80.